Introduction

Mild cognitive impairment (MCI) is considered a transitional stage between normal aging and dementia, in particular Alzheimer’s disease (AD) [1]. The rate of conversion from MCI to AD is approximately 15% per year [2]. However, a substantial number of MCI patients have cognitive complaints caused by other conditions, such as depression, stress, or sleeping disorders. It is important, therefore, for clinicians to identify individuals who are in the prodromal stage of AD, in particular because these patients may be a target for future disease-modifying treatments. Advanced neuroimaging techniques may improve diagnostic accuracy in this patient group. The positron emission tomography (PET) ligand 11C labeled Pittsburgh compound-B ([11C]PIB) [3] detects fibrillary amyloid-beta (Aβ) in vivo, and may be used for this purpose. [11C]PIB PET discriminates well between AD and controls [3,4] and between AD and other types of dementia [5], with the exception of dementia with Lewy bodies [6]. In patients with MCI, little is known about the predictive value of [11C]PIB PET for progression to AD, or about temporal changes in [11C]PIB binding.

Recently, Koivunen and colleagues [7] reported the results of a prospective 2-year follow-up study in which they assessed the predictive value of [11C]PIB PET for progression to AD as well as the temporal changes in amyloid deposition in MCI patients. In the present commentary, we discuss the findings of this study and its potential implications for future clinical trials with disease-modifying agents in prodromal AD.

Identifying prodromal AD with [11C]PIB PET

Koivunen and colleagues [7] performed amyloid imaging with [11C]PIB PET at baseline and after 2 years of follow-up in a sample of 29 MCI patients. They divided MCI patients into converters and non-converters, based on clinical diagnosis at follow-up. At baseline, MCI converters had substantially higher mean [11C]PIB levels compared to MCI non-converters in the posterior cingulate, lateral frontal and temporal cortices and in putamen and caudate nucleus. After classifying [11C]PIB PET scans into either positive or negative, using a cut-off point of 1.5 standardized uptake value ratio (SUVR), 21 of 29 (72%) subjects with MCI had a positive [11C]PIB PET scan. In their study, 15 of these 21 (71%) [11C]PIB-positive MCI patients progressed to AD while only 1 out of 8 (12.5%) [11C]PIB-negative MCI patients did so. These results are in accordance with several previous studies [8,9] and indicate that [11C]PIB PET predicts progression to AD in MCI patients.
Temporal changes in amyloid burden in MCI

Recently, Jack and colleagues [10] proposed a hypothetical model that positioned established and novel biomarkers in the continuum of AD. This model elaborates on the amyloid-cascade hypothesis [11], which states that accumulation of Aβ initiates a cascade of neuro-pathological events, such as the formation of neurofibrillary tangles and neuroinflammation. This may in turn lead to neurodegeneration that presumably is followed by cognitive deterioration and finally results in dementia. Accumulation of Aβ is thought to set in decades before the first cognitive complaints arise, starts to accelerate already in the preclinical stage of AD, and reaches a relative plateau at the time symptoms emerge [12].

In the study by Koivunen and colleagues, the overall amyloid burden in MCI patients increased approximately 2.5% in 2 years. This increase was most prominent for those patients who did not convert to AD. However, the overall increase in amyloid deposition was only modest, whilst hippocampal volumes decreased more strongly. This is in line with the idea that Aβ starts off the cascade whilst hippocampal volumes decreased more strongly. This dissociation between amyloid deposition and structural and functional changes. The findings of Koivunen and colleagues suggest that the time span between deposition of amyloid and actual neurodegeneration may perhaps be shorter than previously assumed, given the dynamic Aβ changes in MCI patients in this study.

The finding of increased amyloid burden over time in MCI patients is consistent with other recent longitudinal amyloid imaging studies. Vilmagne and colleagues [15] reported that 65 MCI patients had a mean increase in [11C]PIB retention of 2.1% over a 20-month follow-up period (annual increase of 1.3%). A study by Jack and colleagues [16] showed an annual increase of 1.7% in 32 MCI patients. Moreover, in an unpublished study from our group in 12 MCI patients, [11C]PIB binding increased by 5.0% over a 30-month period (annual increase 2%). These results are in accordance with the 2.5% increase over 24 months (annual increase 1.25%) reported by Koivunen and colleagues. In all these longitudinal studies, the increased amyloid burden was primarily driven by MCI patients that displayed high [11C]PIB retention at baseline. Taken together, amyloid deposition seems to increase in both MCI converters and non-converters, thereby challenging the theory that amyloid plaque load is stable in the prodromal stage of AD.

A limitation of the study by Koivunen and colleagues, especially given its longitudinal design, is the use of SUVr, which overestimates [11C]PIB binding in comparison with fully quantitative kinetic models [17]. Furthermore, SUVr does not correct for factors that are inherently associated with disease progression, such as heterogeneous flow effects in the region of interest compared to the reference region. We therefore argue that quantitative modeling, and thus dynamic PET scanning, is essential for longitudinal amyloid imaging studies.

Amyloid imaging in clinical trials

The finding that [11C]PIB PET can help identify prodromal AD patients and that most MCI patients show an increased amyloid burden over time may have implications for the design of future clinical trials. First of all, amyloid imaging may be used as an enrichment strategy by enabling the selection of subjects at risk for AD, in order to administer disease-modifying agents to the right patients. Secondly, Aβ PET ligands may be used as a secondary outcome measure to provide biological insight into cognitive primary outcome measures. Finally, amyloid imaging can be applied as a surrogate outcome measure to test whether anti-amyloid therapies are efficacious by measuring the amount of fibrillar Aβ prior to and after the time window of the intervention. In this respect one should note that patients with prodromal AD may still show an increase in amyloid plaque formation, instead of the previously assumed plateau due to an equilibrium between production and clearance of Aβ. This will affect power calculations for such trials. Current development of several fluor-18-labeled amyloid PET tracers (which have a longer half-life time compared to carbon-11) will further increase the availability and applicability of amyloid imaging in both clinical practice and for scientific purposes.

Conclusion

Koivunen and colleagues showed that amyloid imaging may be used to predict clinical progression to AD in patients with MCI and that, contrary to current hypothetical biomarker models, amyloid deposition increases over time in patients with MCI. These findings are relevant for the design of future clinical trials aimed at the prevention of progression to AD by lowering the Aβ burden in the brains of patients with MCI.

Abbreviations

[11C]PIB, 11C labeled Pittsburgh compound-B; Aβ, amyloid-beta; AD, Alzheimer’s disease; MCI, mild cognitive impairment; PET, positron emission tomography; SUVr, standardized uptake value ratio.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, 1007 MB Amsterdam, the Netherlands. 2Department of Nuclear Medicine and PET Research, VU University Medical Center Amsterdam, 1007 MB Amsterdam, the Netherlands.

Published: 19 September 2011
References

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.

2. DeCarli C: Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003, 2:15-21.

3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Längström B: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.

4. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BNM: Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009, 50:191-197.

5. Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA: Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.

6. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA: Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.

7. Kovunen J, Scheinin M, Virta JR, Aalto S, Våhlberg T, Nagen K, Helin S, parkskola R, Vitanen M, Rinne JO: Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011, 76:1085-1090.

8. Forsberg A, Engler H, Almkvist O, Blomqvist G, Hagman Gr, Wall A, Ringheim A, Längström B: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29:1456-1465.

9. Oksello A, Kovunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ: Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 2009, 73:754-760.

10. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowksi QJ: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010, 9:119-128.

11. Hardy JA, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.

12. Engler H, Forsberg A, Almkvist O, Blomqvist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A: Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006, 129:2856-2866.

13. Tosun D, Schuff N, Mathis Chester A, Jagust WJ, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative: Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 2011, 134:1077-1088.

14. Förster S, Grammer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Forst H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A: Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay. Biol Psychiatry 2011 [Epub ahead of print].

15. Villenmann VL, Pike K, Chetelat G, Ellis KA, Mulligan R, Bourgeat P, Ackerman JJ, Jones G, Szweke C, Salvado O, Martin R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC: Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.

16. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Alzheimer’s Disease Neuroimaging Initiative: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009, 132:1353-1365.

17. Yaqub M, Tolboom N, Boellaard R, van Berckel BNM, van Tilburg EW, Luurtsema G, Scheltens P, Lammertsma AA: Simplified parametric methods for 11CPIB studies. Neuroimage 2008, 42:76-86.

doi:10.1186/alzrt88
Cite this article as: Ossenkoppele R, et al.: Amyloid imaging in prodromal Alzheimer’s disease. Alzheimer’s Research & Therapy 2011, 3:26.